This paper analyses an important set of legal issues raised by the telemedical provision of abortion pills. Focusing on the case of European Union (EU) law, it suggests that a properly accredited doctor seeking to treat a patient with abortion pills is entitled, in principle, to rely on EU rules of free movement to protect their access to patients in other member states, and women facing unwanted pregnancies likewise have legal rights to access the services thus offered. EU countries seeking to claim an exception to those rules on the basis of public health or the protection of a fundamental public policy interest (here, the protection of fetal life) will face significant barriers.
| INTRODUCTION
This article explores one set of legal challenges raised by the interplay of two technologies. First, reliance on electronic media opens up the possibility of telemedicine, involving the provision of healthcare services in situations when the health professional and the patient are not in the same location. Second, safe, effective treatment protocols now exist for medical abortion (when a pregnancy is ended using mifepristone and misoprostol-collectively referred to below as 'abortion pills'). Combined, these two technologies open up the possibility of telemedical abortion services. The clinical issues raised by this possibility have been widely considered, 1,2 but the regulatory issues far less so. 3 Much discussion of abortion law has, quite properly, been framed within international human rights norms. Here we consider something different and far less well explored. How does transnational trade law apply to the situation when telemedical abortion services cross national boundaries to enable a woman resident in a country where abortion is illegal or highly restricted to end an unwanted pregnancy?
Can residents of these countries rely on transnational trade law to assert rights to receive telemedical abortion services? And can health professionals claim a legally protected right to treat them?
While this discussion raises issues that resonate in other regional contexts and other regulatory frameworks, we focus on how these issues might play out within the European Union (EU). The EU has a highly developed set of uniform regulations governing transnational trade and wide variation in domestic abortion laws. While there has been a gradual trend towards more permissive regulation of abortion within Europe, there nonetheless exists significant variation, with termination of pregnancy available on request within specified gestational limits in some countries (including the Netherlands, Sweden, and France), but permitted only in highly restricted circumstances in others (such as Northern Ireland, Malta, and Poland). 4 When legal local abortion services are not available, women will either travel to access services in other countries or end pregnancies outside of formal healthcare settings. 5 Many of these women will seek to have abortion services travel to them, through the online purchase of abortion pills.
Abortion pills are readily available on the internet from a range of suppliers. Some will supply pills without a medical prescription, and some of the pills supplied will not contain the indicated quantity of the active medical ingredient. 6 We do not consider those situations here; rather, we focus on the case in which authentic pills are supplied on prescription by an appropriately accredited doctor based in another EU country. This brings legal issues of free movement of medicines and services into particularly sharp focus. When articulated in the language of EU law, these issues can appear very technical and far removed from the fundamental moral issues that underpin them.
This should not conceal what is at stake here: the responsible conduct of medical practice in supporting women's reproductive health, the proper role of telemedical services in allowing women to escape domestic criminal prohibitions that reflect religious and moral concerns for the protection of embryonic and fetal life (hereinafter fetal life), and the reach of EU law into sensitive moral matters.
| ABORTION USING PILLS PURCHASED ONLINE
The safety, effectiveness, and patient acceptability of abortion pills is well established, 7, 8 Although evidence suggests that the service offered by these groups is very safe and highly acceptable to those who use it, 11 it is subject to one important limitation: the medical treatment offered necessarily ends with provoking a miscarriage. This means that women must seek medical treatment locally for any complications that arise.
Serious infections requiring hospitalization are very rare and it is only in the most extreme circumstances (estimated at 0.03% of cases) that women require transfusion to replace excessive blood loss.
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However, haemorrhage can be life-threatening if left untreated and women are advised to plan for it. WoW and WHW emphasize that this makes a planned miscarriage considerably safer than if the same thing occurs spontaneously, and that women often manage spontaneous miscarriages by themselves at home, with limited medical supervision.
Research suggests that, given appropriate information, women can safely self-assess to confirm whether the termination is complete or whether further care is needed. 13 It is also important to remember that the risks of a telemedical abortion should be measured against the risks implicit in the other options available to women. First, alongside the social, emotional, and financial harms that come with continuing an unwanted pregnancy to term are the very real clinical risks of so doing: pregnancy and childbirth carries a significantly higher risk of morbidity and mortality than a safely performed abortion, particularly in early pregnancy. 8, 14 Second, while less well documented, the need to travel to obtain an abortion has negative emotional, financial, and health consequences, 15 not least in delaying access to services resulting in later, higher risk procedures. Third, when unable to access safe abortion services, some women will try other extreme measures to end a pregnancy, which are often either exceedingly dangerous, likely to be ineffective, or both. It is noteworthy that the availability of abortion pills is credited with making a contribution to the global reduction in the number of women dying or seeking aftercare for severe complications following illegal abortion each year.
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There is thus good reason to believe that the telemedical abortion services offered by WoW and WHW meet the best standards of patient care and safety available, given the context in which they are offered. Indeed, an Austrian court has recognised that WoW's work has made a material contribution to women's health and survival.
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The groups offer women a choice that allows them to avoid the risks of other, often unsafe, methods of abortion and the significant physical, emotional, social, and financial burdens of continuing an unwanted pregnancy. However, highly controversially, they also enable women to avoid domestic legal prohibitions on abortion. ), but also a significant web of legislation adopted by the EU institutions that applies to trade within the EU.
Second, EU law includes mechanisms whereby individual traders (service providers and receivers or, in our case, health professionals and their patients) may enforce their rights using courts. This is relatively unusual:
trade agreements usually provide only for interstate dispute settlement and/or arbitration. Third, EU law adopts a highly restrictive approach to rules that have the effect of trade protectionism. Any restriction of access to markets is treated as suspect. Impeding market access must be carefully justified, and must be a proportionate restriction on trade.
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From the point of view of those seeking to provide and receive telemedical abortion services, EU law offers a number of important potential protections. So long as a health professional complies with the domestic law within the country in which they work when treating their patients, the starting principle is that they can use rights to trade in order to reach patients in other countries who wish to be treated by them. EU law gives enforceable rights to the health professional to offer the service, and to the patient to receive it. Attempts to prosecute either can also be met with a defence that the prosecution breaches EU law. 
| JUSTIFIED STATE INTERVENTIONS
No trade agreement, even one of the depth, intensity, and enforceability of EU law, removes entirely states' sovereign entitlements over important matters of public policy or morality, promoting or protecting health, or securing human rights. Non-tariff barriers do not breach EU law if they are necessary to protect such public interests. One might thus assume that it would be easy for European states to argue that their abortion laws protect the broad purposes for which they were generally historically intended-to protect women's health and/ or to recognise the special moral status of the fetus-and thus avoid any application of EU law to cross-border abortion by telemedicine.
However, several features of EU law suggest that it would not be as straightforward as one might expect to assert such an exemption, thus leaving scope for doctors providing or patients receiving such services successfully to rely on EU law to defend their activities. policy interest (here, the protection of fetal life) will face significant barriers. The legal burden of establishing that a derogation from free movement rules can be justified lies on the EU country concerned.
While again we have had no space to consider this further here, similar protections may be available under other trade agreements.
It is important to re-emphasize that the focus of our argument is restricted to the case of properly accredited doctors, acting within the law of the country from which they operate, to supply authentic abortion pills on prescription. Within those limited circumstances, we believe that EU trade law is properly interpreted so as to offer important protections both to doctors and their patients. How the protections thus offered would translate into enforceable rights raises a further set of complexities that will depend in part on the specific national context and go far beyond the scope of this paper (and we have offered a more detailed exploration of one national context elsewhere ). However, they are likely to offer a basis for legal challenge to any attempt by local authorities to prevent the physical importation of abortion pills, and to require that, insofar as possible, domestic law be interpreted so as to render it consistent with these international trade obligations. This is not to deny that any relevant litigation would raise a range of difficult legal questions that have not been fully tested in the courts. As such, the legal pathway to challenging an attempt to prevent the prescription of abortion pills for a patient in one country from a prescribing doctor in another would inevitably be long, expensive, and contested.
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